Benitec Biopharma Inc BNTC 深 沪
等待开盘 02-06 09:30:00 美东时间
11.65
-0.760
-6.12%
华盛通- 最 高12.53
- 今 开12.32
- 成交量 11.83万股
- 最 低 11.53
- 昨 收 12.41
- 总市值 3.94亿
- 52周最高 17.15
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 9.80
- 委 比 -60.00%
- 总股本 3386.22万
- 历史最高 5609.5744
- 量 比 1.05
- 振 幅 8.06%
- 历史最低 2.227
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma Inc. reported interim results from its BB-301 Phase 1b/2a study for OPMD-related dysphagia. Patient 1 showed durable disease-modifying effects at 24 months post-treatment, with significant improvements in pharyngeal residue and dysphagic symptoms. All four Cohort 1 patients demonstrated sustained response to BB-301 at 12 months, meeting predefined criteria. BB-301 uses a unique " Silence and Replace" mechanism targeting mutant P...
01-11 13:00
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting
Benitec Biopharma ( ($BNTC) ) has shared an update. On December 1, 2025, Benite...
2025-12-03 06:48
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma (NASDAQ:BNTC) with a Buy and lowers the price target from $35 to $32.
2025-11-24 21:06
Benitec GAAP EPS of -$0.22
Benitec press release (BNTC): Q1 GAAP EPS of -$0.22. Total Expenses for the quarter ended September 30, 2025, were $9.8 million compared to $5.8 million for the quarter ended September 30, 2024. The C...
2025-11-15 06:45
快讯 | Benitec Biopharma Inc：Leerink Partners将目标价从20美元下调至18美元
Benitec Biopharma Inc : Leerink Partners Cuts Target Price to $18 From $20
2025-11-11 20:12
Benitec Biopharma prices $100M stock offering
Benitec Biopharma (BNTC) priced its underwritten public offering of ~5.93M shares and a concurrent registered direct offering of ~1.48M shares with long-term investor Suvretta Capital. Each share of...
2025-11-06 13:59
Benitec Biopharma Announces Underwritten Common Stock Offering; Terms Not Disclosed
Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference
2025-11-06 05:44
Benitec Biopharma Inc. Announces Proposed Public Offering
Benitec Biopharma Inc. has launched an underwritten public offering of its common stock and a concurrent registered direct offering with Suvretta Capital. The company also granted underwriters a 30-day option to purchase additional shares. The offerings are expected to close on November 7, 2025, subject to market and customary conditions. Leerink Partners, TD Cowen, and Evercore ISI are acting as bookrunning managers. A prospectus supplement has ...
2025-11-05 21:43
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
